PLENARY SPEAKER

Ayman El-Kattan, PhD

Head of DMPK @ IFM Therapeutics

ECCS Class 3A: Interaction of Gabapentin and Its Analogues with Transporters - A Love-Hate Relationship

PLENARY SPEAKER

Daniel Price, PhD

Vice President, Computational Chemistry & Structural Biology @ Nimbus Therapeutics

ADMET In The Age of AI

Alison Betts, PhD

Global Head of DMPK and Modeling @ Takeda

Use of PK/PD Modeling to Understand the Potential and Pitfalls of New Modalities- Picking the Winners from the Losers

Laigao Chen, PhD

Director, Digital Medicine & Translational Imaging @ Pfizer

Measurement of Target Exposure and Binding with Positron Emission Tomography (PET) Imaging in Drug Research and Development

Karissa Cottier, PhD

Senior Scientist, ADME Product & Application Development @ BioIVT

Fatty Liver Disease Modeling  In a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC): Applications In Drug Development & Screening

Jonathan Jackson, PhD, DABT

Senior Principal Scientist, Discovery Toxicology @ Pfizer

Early Drug-Induced Liver Injury Risk Screening: “Free,” as Good as it Gets

Hema Muralidharan, PhD

Scientist @ Moderna

Utilizing Ex Vivo Liver Slice Models for Preclinical Evaluation of LNP-Based mRNA Delivery

Thien-Khoi (TK) Phung, PhD

Principal Scientist I @ Novartis Institutes for Biomedical Research

Dynamical Modeling of Protein Degradation to Improve Compound Selection in Drug Discovery

Birk Poller, PhD

Associate Director, In Vitro ADME Group @ Novartis, Basel, Switzerland

Liver MPS Model Comparison for Clearance IVIVC

Christopher Rowbottom, PhD

Associate Scientific Director @ Moderna

Pharmacokinetics and Distribution of Lipid Nanoparticles

Ben Scruggs, PhD

CEO & Board Member@ Altis Biosystems

Overcoming Limitations of Caco-2 Cells for ADME Using Adult Human Crypt-Derived Planar Intestinal Epithelium Cultures

 Matt Silva, PhD

CEO @ Emit Imaging

Cryo-Fluorescence Tomography: Transformative 3D Imaging to Monitor Drug PK/D